{"id":"W3042190218","doi":"10.1016/j.ejca.2020.05.010","title":"Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma","year":2020,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":79,"is_retracted":false,"has_abstract":false,"ca_institutions":"Hospital for Sick Children","funders":"Fondation contre le Cancer; Vlaamse regering; Kom op tegen Kanker; Fonds Wetenschappelijk Onderzoek; National Cancer Institute; Cancer Research UK; Neuroblastoma UK; Oak Foundation; Olivia Fund; Instituto de Salud Carlos III; Alex's Lemonade Stand Foundation for Childhood Cancer","keywords":"Neuroblastoma; Medicine; Clinical trial; Drug development; Drug; ATRX; Oncology; Pharmacology; Internal medicine; Biology; Mutation; Genetics","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002517712,0.0009824501,0.001525021,0.002641928,0.000287024,0.001490309,0.0008317438,0.001845447,0.004175178],"category_scores_gemma":[0.002025132,0.0003389673,0.001066893,0.002372432,0.0003050521,0.001614322,0.001084598,0.003059407,0.001532389],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001795161,"about_ca_system_score_gemma":0.00531246,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003258004,"about_ca_topic_score_gemma":0.009739438,"domain_scores_codex":[0.9995399,0.00007117195,0.00007106343,0.00005917323,0.0001850629,0.0000738087],"domain_scores_gemma":[0.9986909,0.0005486773,0.000193991,0.0000215677,0.0003917071,0.0001532758],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001636538,0.0001187287,0.0001838443,0.02373695,0.0001269389,0.0001465963,0.00005850323,0.0004962531,0.001498505,0.005486303,0.1150381,0.8529455],"study_design_scores_gemma":[0.00006986045,0.0001491736,0.0006240832,0.008506615,0.0002072919,0.0003056418,0.0000284507,0.0001096138,0.0005007739,0.0008408328,0.9886409,0.00001679996],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0001191484,0.995317,0.0001553254,0.001516515,0.001017756,0.00003047123,0.00009919491,0.00001357829,0.001731018],"genre_scores_gemma":[0.000492431,0.9967043,0.0003460281,0.001219407,0.0002866258,0.00002235562,0.0001111788,0.000003042312,0.0008146227],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.004175178,"threshold_uncertainty_score":0.01396739,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04454238105661854,"score_gpt":0.3303695918244042,"score_spread":0.2858272107677856,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}